- Home
- Publications
- Publication Search
- Publication Details
Title
Combination therapy patents: a new front in evergreening
Authors
Keywords
-
Journal
NATURE BIOTECHNOLOGY
Volume 39, Issue 12, Pages 1504-1510
Publisher
Springer Science and Business Media LLC
Online
2021-12-09
DOI
10.1038/s41587-021-01137-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma
- (2021) Simon Chowdhury et al. Clinical Genitourinary Cancer
- Identifying potential prescription drug product hopping
- (2021) Vrushab Gowda et al. NATURE BIOTECHNOLOGY
- Registration trials in countries without access to US standards of care — pitfalls of interpretation
- (2021) Garth W. Strohbehn et al. Nature Reviews Clinical Oncology
- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
- (2020) Paola Ciciola et al. Journal of Clinical Medicine
- Opportunities for using In Silico ‐Based Extended Dosing Regimens for Monoclonal Antibody Immune Checkpoint Inhibitors
- (2020) Cody J. Peer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- 702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
- (2020) S. Pal et al. ANNALS OF ONCOLOGY
- LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
- (2020) Z. Lwin et al. ANNALS OF ONCOLOGY
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
- (2020) A.M. Arance Fernandez et al. ANNALS OF ONCOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Tertiary patenting on drug–device combination products in the United States
- (2018) Reed F Beall et al. NATURE BIOTECHNOLOGY
- Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology
- (2018) Bruno Kovic et al. JAMA Internal Medicine
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Combining drugs and extending treatment — a PFS end point is not sufficient
- (2017) Bishal Gyawali et al. Nature Reviews Clinical Oncology
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
- (2015) Chul Kim et al. JAMA Internal Medicine
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- The misguided ethics of crossover trials
- (2013) Vinay Prasad et al. Contemporary Clinical Trials
- Evergreening: a common practice to protect new drugs
- (2011) Kate S Gaudry NATURE BIOTECHNOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now